Compare
Iridex Corp vs Electromed, Inc. vs Stereotaxis, Inc. vs electroCore, Inc.
| Latest fiscal year | Iridex Corp IRIX | Electromed, Inc. ELMD | Stereotaxis, Inc. STXS | electroCore, Inc. ECOR |
|---|---|---|---|---|
| Year ended | 2026-01-03 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $52.67M | $73.78M | $32.38M | $32.03M |
| Revenue growth (YoY) | +8.2% | +15.3% | +20.3% | +27.2% |
| Gross margin | 36.5% | 78.5% | 52.7% | 86.8% |
| Operating margin | -4.9% | 18.8% | -68.3% | -41.1% |
| Net margin | -8.4% | 15.3% | -66.8% | -43.6% |
| Net income | -$4.44M | $11.30M | -$21.64M | -$13.97M |
| EPS (Diluted) | -$0.26 | $1.30 | -$0.25 | -$1.65 |
| Operating cash flow | -$2.12M | $9.66M | -$13.69M | -$8.19M |
| Free cash flow | -$2.26M | $8.41M | -$13.78M | -$8.25M |
| Cash & equivalents | $6.03M | $20.45M | $13.42M | $7.04M |
| Total assets | $29.15M | $66.27M | $52.25M | $18.67M |
| Total liabilities | $24.23M | $12.29M | $33.53M | $20.38M |
| Shareholders' equity | $4.92M | $53.98M | $13.48M | -$1.71M |
| Return on year-end equity | -90.1% | 20.9% | -160.5% | n/a |
| Shares outstanding | 17.31M | 8.37M | n/a | 8.00M |
Revenue, most recent five fiscal years
| Fiscal year | Iridex Corp | Electromed, Inc. | Stereotaxis, Inc. | electroCore, Inc. |
|---|---|---|---|---|
| Latest | $52.67M Ended 2026-01-03 | $73.78M Ended 2026-06-30 | $32.38M Ended 2025-12-31 | $32.03M Ended 2025-12-31 |
| 1 year earlier | $48.67M Ended 2024-12-28 | $64.00M Ended 2025-06-30 | $26.92M Ended 2024-12-31 | $25.18M Ended 2024-12-31 |
| 2 years earlier | $51.87M Ended 2023-12-30 | $54.72M Ended 2024-06-30 | $26.77M Ended 2023-12-31 | $16.03M Ended 2023-12-31 |
| 3 years earlier | $56.97M Ended 2022-12-31 | $48.07M Ended 2023-06-30 | $28.15M Ended 2022-12-31 | $8.59M Ended 2022-12-31 |
| 4 years earlier | $53.90M Ended 2022-01-01 | $41.66M Ended 2022-06-30 | $35.02M Ended 2021-12-31 | $5.45M Ended 2021-12-31 |